

ADVAC 2026

DRAFT PROGRAM

AS OF 25 FEBRUARY 2026

MONDAY 11 MAY 2026

TBC	Bus from hotels to Les Pensières		
9:00-9:30	Opening and Objectives of the course	Kamel Senouci, Director ADVAC, University of Geneva	Charles Mérieux conf. room
9:30-9:40	Welcome and Logistic briefing	Sandra Angèle, Director, Les Pensières, Fondation Mérieux	Charles Mérieux conf. room
SESSION 1: THE VACCINE JOURNEY: FROM VACCINES TO VACCINATION & THE IMPACT OF VACCINES			Chair: Arnaud Didierlaurent, University of Geneva
9:40-10:05	1. From Research to individual protection: The A-to-Z vaccine's journey	Arnaud Didierlaurent and Kamel Senouci, University of Geneva, Switzerland	Charles Mérieux conf. room
10:05-10:25	Discussion		
10:25-10:55	Break		Restaurant
10:55-11:20	2. Vaccines Preventable Diseases' Burden and Vaccines Impact on Public Health	Kamel Senouci, University of Geneva	Charles Mérieux conf. room
11:20-11:40	Discussion		Charles Mérieux conf. room
11:40-12:05	3. Measuring vaccination's impact in populations	Brad Gessner, Independent expert	
12:05-12:25	Discussion		
12:25-13:25	Lunch (seated, please check the tables attributed to the speakers)		Restaurant + Ogobara Doumbo room
13:25-13:50	4. Where are we with vaccine-preventable diseases & immunization coverage worldwide: the state of the immunization	Kate O'Brien, WHO, Geneva	
13:50-14:10	Discussion		Charles Mérieux conf. room
14:10-14:35	5. Using vaccines to address a public health problem: the example of Polio eradication immunization strategy	Ananda Bandyopadhyay, Gates Foundation, USA	Charles Mérieux conf. room
14:35-14:55	Discussion		
14:55-15:20	6. GAVI model to support countries immunization program	Marta Tufet, GAVI	
15:20-15:40	Discussion		
15:40-15:55	Evaluation		
15:55-16:30	Break		Restaurant
16:30-17:15	Meet your mentor		TBC
17:15-18:15	Self-presentation of participants (background, interests in life...)	Social Event	Nicole Mérieux room
18:15-20:00	Welcome Reception		Nicole Mérieux room + Terrasse
20:00	Bus to Hotels		

TUESDAY 12 MAY 2026

TBC

Bus from hotels to Les Pensières

SESSION 2: HOW VACCINES WORK?

Chair:
Kamel Senouci,
Director
ADVAC, UNIGE

09:00-09:25	7. How do vaccines protect? Immune effectors induced by vaccines: Antibodies, B and T cells, mucosal immunity	Christiane Eberhardt , University of Geneva, Switzerland	
09:25-09:45	Discussion		
09:45-10:10	8. How are vaccines' responses elicited? What a vaccinologist should know about the basic aspects of immunological responses	Arnaud Marchant , Université Libre de Bruxelles, Belgium	Charles Mérieux conf. room
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	9. How to use vaccines' platforms to tailor immune responses?	Arnaud Didierlaurent , University of Geneva, Switzerland	
11:25-11:45	Discussion		
11:45-12:10	10. Use and limitations of correlates of immunity in vaccinology	Adam Finn , University of Bristol, UK	Charles Mérieux conf. room
12:10-12:30	Discussion		
12:30-14:00	Lunch		Restaurant + O. Doumbo room
14:00-15:30	Interactive Session 1 and Q&A Variability of vaccine responses in the real world	Christiane Eberhardt , University of Geneva, Switzerland & Arnaud Marchant , Université Libre de Bruxelles, Belgium	Charles Mérieux + Simone Mérieux
15:30-15:55	11. Immunological memory	Rafi Ahmed , Emory University, USA	Charles Mérieux
15:55-16:15	Discussion		
16:15-16:45	Break		Restaurant
16:45-17:10	12. Non-specific effects of vaccines	Nigel Curtis , The Royal Children's Hospital, Melbourne, Australia	Charles Mérieux
17:10-17:30	Discussion		

SESSION 3 – VACCINE TECHNOLOGY & MANUFACTURING (PART 1/3)

Chair: Arnaud
Didierlaurent

17:30-17:55	13. Vaccine market, market shaping and regional initiatives for vaccine production	Georgios Stathopoulos , WHO, Switzerland	Charles Mérieux
17:55- 18:15	Discussion		
18:15-18:30	Evaluation		
18:30-19:30	Soccer, Karaoke, Mølky, Pétanque....	Social Event	Outside
19:45-21:00	Drinks and Dinner		TBC
21:00	Bus to Hotels		

WEDNESDAY 13 MAY 2026

TBC

Bus from hotels to Les Pensières

SESSION 3 – VACCINE TECHNOLOGY & MANUFACTURING (PART 2/3)

Chair: Arnaud Didierlaurent
± E. Erbeling,

09:00-09:25	14. Landscape in vaccine and immunization technologies- platform-production (include nasal vaccine)	Emily Erbeling (Independent expert)	
09:25-09:45	Discussion		Charles Mérieux
09:45 -10:10	15. Concepts of Chemistry, Manufacturing, and Controls (CMC) for vaccines	Ozzie Berger, IAVI, USA	conf. Room
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	16. From inception to regulatory submission	Rick Malley, Boston Children Hospital, USA	
11:25-11:45	Discussion		
11:45-12:10	17. The complexity of quality control in vaccine manufacturing	Philippe Juvin, Sanofi Pasteur, France	Charles Mérieux
12:10-12:30	Discussion		
12:30-13:45	Lunch		Restaurant + O. Doumbo

SESSION 4 – VACCINE REGULATORY

Chair: Emily Erbeling

13:45-14:10	18. The role of Regulatory Agencies, Issues and Challenges of submitting a dossier (including content of a dossier)	Marco Cavaleri, EMA, The Netherlands	
14:10-14:30	Discussion		
14:30-16:00	Small Group Exercise 1 (Part 1): Vaccine Regulatory 4 Groups: <ul style="list-style-type: none"> ○ 1. Ozzie Berger & Norman Baylor ○ 2. Arnaud Didierlaurent & Donna Boyce ○ 3. Olga Rovira & Luis Jodar ○ 4. Marco Cavaleri & Veronica Gambillara-Fonck 	Norman Baylor, Biologics Consulting Group, US Ozzie Berger, IAVI, USA, Donna Boyce, Pfizer USA, Marco Cavaleri, EMA, Netherland, Arnaud Didierlaurent, UNIGE, Switzeland, Veronica Gambillara-Fonck, Pureos Bioventures, Switzerland, Luis Jodar (independent expert), Olga Rovira, Kontivax, Belgium.	Different rooms
16:00-16:30	Break		Restaurant
16:30-16:45	Small Group Exercise 1 (Part 2): Debriefing	All groups	
16:45-18:15	Optional lecture: Interactive Session 2 From ideas to implementation - the realities of funding for vaccine research and development in the private sector	DCVMN and IFPMA members	Check Information boards
18:15-18:30	Evaluation		

Special lecture: THE 10th LAMBERT LECTURE

18:30-18:35	Introduction	Paul-Henri Lambert	
18:35-19:00	19. Immune Fitness	John S. Tsang, Yale University, USA	Charles Mérieux
19:00-19:20	Discussion		
19:20	Dinner		
21:00	Bus to Hotels		

THURSDAY 14 MAY 2026

TBC

Bus from hotels to Les Pensières

SESSION 3 – VACCINE TECHNOLOGY & MANUFACTURING (PART 3/3)

Chair: Emily Erbelding,

09:00-09:25 20. Delivering outbreaks vaccine in 100 Days: What does it take? Aurelia Nguyen, CEPI, UK

09:25-09:45 Discussion

09:45-10:45 Interactive session 3 and Q&A

What can go wrong in vaccine development?

Panelists:

Rosane Cuber, Bio-Manguinhos, Brazil

Luis Jodar (independent expert)

Rick Malley, Boston Children Hospital, USA

Emily Erbelding (independent expert)

Charles Mérieux
Conf room

10:45-11:00 Break

Restaurant

SESSION 5 – ASSESSING VACCINES IN CLINICAL TRIALS (Part 1/2)

Chair: Edwin Asturias,
Children's Hospital
Colorado, USA

11:00-11:25 21. Clinical trials: an overview of issues to be considered Andrew Pollard, Oxford Vaccine Group, UK

11:25-11:45 Discussion

Charles Mérieux

11:45-12:10 22. Introduction to statistical aspects of clinical trials Martha Nason, PATH, USA

12:10-12:30 Discussion

12:30-13:00 Working lunch:

Participants eat at the Restaurant with their group and go back to their room for the SGE 2

Restaurant

13:00-15:15 Small Group Exercise 2:

How to design, recruit volunteers for, and analyze the results of selected phase II trials

7 Groups:

Group 1: S. Aureus: V. Gambillara & B. Gessner

Group 2: Ebola: M. Nason & R. Libster

Group 3: Dengue: N. Baylor & A. Durbin

Group 4: RSV: E. Asturias & K. Talaat

Group 5: Mpox: K. Johansen

Group 6: Typhoid conjugate vaccines: K. Senouci

Group 7: Coronavirus: E. Erbelding

Check Group assignment and rooms on boards

15:15-15:40 23. Assessing herd protection and vaccine effectiveness (and use for licensure) John Clemens, International Vaccine Institute (IVI), Republic of Korea

Charles Mérieux

15:40-16:00 Discussion

16:00-16:30 Break

Restaurant

16:30-16:55 24. A to Z for vaccines clinical trials Romina Libster, Fundacion INFANT, Argentina

16:55-17:15 Discussion

17:15-17:40 25. Human Challenge Trials or other ways of assessing vaccine efficacy Chris Chiu, Imperial College London, UK

Charles Mérieux

17:40-18:00 Discussion

18:00-18:15 Evaluation

18:15-19:30 Dinner

Restaurant + O.Dumbo room

19:30 Bus to Hotels

FRIDAY 15 MAY 2026

TBC

Bus from hotels to Les Pensières

SESSION 6 – VACCINE SAFETY - ASSESSMENT OF ADVERSE EFFECTS

Chair: Kari Johansen, Public Health Agency, Sweden

09:00-09:25	26. How do vaccines cause adverse events? (Including Immune-mediated diseases)	Kawsar Talaat , Johns Hopkins Bloomberg School of Public Health, USA	
09:25-09:45	Discussion		Charles Mérieux
09:45-10:10	27. WHO Guidance on how to detect and manage safety issues	Madhav Balakrishnan , WHO, Switzerland	Conf room
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	28. Population-based post-licensure surveillance (including study methodology for signal validation and epi studies)	Kaatje Bollaerts , P95, Belgium	
11:25-11:45	Discussion		Charles Mérieux
11:45-12:10	29. Immunization safety, logistic and vaccine management in vaccination programs	Kamel Senouci , University of Geneva	
	CTC, VVM		
12:10-12:30	Discussion		
12:30-14:00	Lunch		Restaurant + Ogobara Doumbo

SESSION 5 – ASSESSING VACCINES IN CLINICAL TRIALS (Part 2/2)

14:00-14:30	Mentoring		
14:30-16:40	Small group exercise 3: Vaccine trial Phase III planning, implementation, analysis of the study results	7 Groups: Group 1: V. Gambillara Group 2: M. Nason & R. Libster Group 3: N. Baylor & A. Durbin Group 4: E. Asturias & K. Talaat Group 5: K. Johansen Group 6: K. Senouci Group 7: E. Erbeling	Charles Mérieux O. Doumbo Nicole Mérieux Simone Mérieux Mandallaz Chavoires Salon du Dr
16:40-14:55	Evaluation		
16:55-17:10	Break		Restaurant

Special lecture: THE 18TH PLOTKIN LECTURE

17:10-17:15	Introduction	Edwin Asturias , Children's Hospital Colorado, USA	
17:15-17:40	30. Advancing CMV Vaccine Strategies: From Bench to Bedside	Sallie Permar , Cornell University, USA	Charles Mérieux
17:40-18:00	Discussion		
18:00-20:00	Reception Dinner		Restaurant + O. Doumbo
20:00	Bus to Les Pensières		

SATURDAY 16 MAY 2026

TBC Bus from hotels to Les Pensières

SESSION 7 - ETHICAL ISSUES

Chair: Kari Johansen, Public Health Agency, Sweden

09:00-09:25	31. Applied ethics in immunization programs and practice	Anuradha Rose , Christian Medical College of Vellore, India	
09:25-09:45	Discussion		Charles Mérieux conf room
09:45-10:10	32. Principles, guidelines and frameworks for ethical considerations in clinical trials of vaccines	Catherine Slack , University of KwaZulu-Natal, South Africa	
10:10-10:30	Discussion		
10:30-10:50	Break		Restaurant
10:50-13:00	Small group exercise 4: Ethical considerations in vaccine trials	Facilitators (7 Groups): Edwin Asturias, Kari Johansen, Anuradha Rose, Louise Henaff, Catherine Slack, Martha Nason, Kawsar Talaat.	Check rooms' assignments on boards
13:00-13:10	Evaluation		
13:10-13:40	Lunch		Take away or eat at the Restaurant
13:40	Bus to Hotels and Free time in the afternoon		
TBC	Bus from Hotels to Les Pensières		
TBC	Dinner upon Registration		Restaurant
TBC	Bus from Les Pensières to Hotels		

SUNDAY 17 MAY 2026

TBC Bus from hotels to Les Pensières (for dinner only)

TBC Dinner upon registration Restaurant

TBC Bus from Les Pensières to Hotel

MONDAY 18 MAY 2026

TBC Bus from hotels to Les Pensières

09:00-09:10	Ethical considerations in vaccine trials: Recap	Catherine Slack , University of KwaZulu-Natal, South Africa	Charles Mérieux conf. Room
-------------	--	--	----------------------------

SESSION 8 – DECISION MAKING FOR VACCINES (Part 1/2)

Chair: Louise Henaff, UNIGE

09:10-09:35	33. The decision-making processes for vaccines use: global, regional and local perspectives	Rudzani Muloiwa , University of Cape Town, South Africa	
-------------	--	--	--

09:35-09:55	Discussion		Charles Mérieux
-------------	------------	--	-----------------

09:55-10:20	34. The example of the WHO SAGE decision making processes (GRADE)	Melanie Marti , WHO Geneva, Switzerland	
-------------	--	--	--

10:20-10:40	Discussion		
-------------	------------	--	--

10:40-11:10	Break		Restaurant
-------------	-------	--	------------

11:10-11:35	35. The decision-making processes for vaccines' use: what should experts consider	Kari Johansen , Public Health Agency of Sweden	
-------------	--	---	--

11:35-11:55	Discussion		Charles Mérieux
-------------	------------	--	-----------------

11:55-12:20	36. The role of health economics (including modelling) as a tool in analyzing vaccine policy options	Marc Brisson , Université de Laval, Canada	
-------------	---	---	--

12:20-12:40	Discussion		
-------------	------------	--	--

12:40-13:40	Lunch		Restaurant
-------------	-------	--	------------

13:40-15:50	Small group exercise 5 Decision-making for the evaluation and impact assessment of new vaccines introduced in selected countries: safety and effectiveness.	7 Groups: <ul style="list-style-type: none"> • Group 1: Rotavirus: M. Iturriza • Group 2: HPV: K. Senouci • Group 3: Dengue LMICs: H. Nohynek • Group 4: Zoster: K. Johansen • Group 5: Malaria: K. Neuzil • Group 6: RSV Adults: K. Talbot • Group 7: RSV: J. Englund 	Check rooms' assignments on boards
-------------	--	--	------------------------------------

15:50-16:20	Break		Restaurant
-------------	-------	--	------------

SESSION 9 – UPDATES ON VACCINES (part 1/4)

Chair: Anna Durbin, Johns Hopkins School of Public Health, USA

16:20-16:45	37. Polysaccharide and conjugate vaccines	David Goldblatt , University College London, UK (online)	
-------------	--	---	--

16:45-17:05	Discussion		
-------------	------------	--	--

17:05-17:30	38. Pneumococcal conjugate vaccines: the impact of PCV, its introduction in different populations (including adults & children) and the change in PCV valency stereotypes	Keith Klugman , Gates Foundation, USA (online)	Charles Mérieux conf. Room
-------------	--	---	----------------------------

17:30-17:50	Discussion		
-------------	------------	--	--

17:50-18:05	Evaluation		
-------------	------------	--	--

18:05-19:05	Book your Mentor		
-------------	------------------	--	--

19:05-20:35	Dinner		Restaurant + O. Doumbo
-------------	--------	--	------------------------

20:30 Bus to Hotels

TUESDAY 19 MAY 2026

TBC

Bus from hotels to Les Pensières

SESSION 9 – UPDATES ON VACCINES (part 2/4)

Chair: Anna Durbin, Johns Hopkins School of Public Health, USA

09:00-09:25	39. HPV vaccines	Deborah Watson-Jones , London School of Hygiene and Tropical Medicine & Mwanza Intervention Trials Unit (MITU) Tanzania	Charles Mérieux conf. Room
09:25-09:45	Discussion		
09:45-10:10	40. Typhoid vaccines	Kathy Neuzil , Gates Foundation	
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	41. Malaria Vaccines	Simon Draper , University of Oxford, UK	
11:25-11:45	Discussion		
11:45-12:10	42. Vaccines against arboviruses (Dengue, Zika, Chikungunya)	Anna Durbin , Johns Hopkins Bloomberg School of Public Health, USA	Charles Mérieux
12:10-12:30	Discussion		
12:30-14:00	Lunch		Restaurant + O. Doumbo
14:00-14:25	43. Rotavirus and norovirus vaccines	Miren Iturriza , Gates Foundation	Charles Mérieux
14:25-14:45	Discussion		

SESSION 8 – DECISION MAKING FOR VACCINES (Part 2/2)

Chair: Anna Durbin, Johns Hopkins School of Public Health, USA

14:45-15:45	Small group exercise 6 Sharing recommendations with the Minister of Health	Restitution of the 7 Groups from Exercise 5	Charles Mérieux
15:45-16:15	Break		Restaurant

SESSION 9 – UPDATES ON VACCINES (part 3/4)

Chair: Anna Durbin, Johns Hopkins School of Public Health, USA

16:15-16:40	44. Annual strain adaptation: the examples of Flu and COVID vaccines	Kanta Subbarao , Université de Laval, Canada	
16:40-17:00	Discussion		
17:00-17:25	45. Combination vaccines	Hanna Nohynek , Finnish Institute for Health and Welfare, Finland	Charles Mérieux
17:25-17:45	Discussion		
17:45-18:10	46. Vaccines for Non-Communicable Diseases	Joachim Hombach , University of Geneva, Switzerland	
18:10-18:30	Discussion		
18:30 - 18:45	Evaluation		
18:45-19:15	Debate "Mandatory vs voluntary vaccination"	Rudzani Muloiwa & Kathy Neuzil	Nicole Mérieux
19:15-20:30	Aperitive and Dinner		Restaurant + O. Doumbo
20:30	Bus to Hotels		

WEDNESDAY 20 MAY 2026

TBC

Bus from Hotels to les Pensières

Chair: Hanna Nohynek, Finnish Institute for Health and Welfare, Finland

SESSION 10 - SELECTING APPROPRIATE VACCINATION STRATEGIES

09:00-09:25	47. RSV and GBS vaccines	Janet Englund, University of Washington/Seattle Children's Hospital Seattle, USA	
09:25-09:45	Discussion		Charles Mérieux
09:45-10:10	48. Vaccination and pregnancy and early life	Christiane Eberhardt, University of Geneva, Switzerland	conf. Room
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	49. Vaccination schedules: Past, present and future - is there some rationale?	Edwin Asturias, Children's Hospital Colorado, USA	
11:25-11:45	Discussion		
11:45-12:10	50. Vaccine responses and efficacy in the elderly	Keipp Talbot, Vanderbilt University, USA	Charles Mérieux
12:10-12:30	Discussion		
12:30-12:55	51. Vaccination in immuno-compromised individuals	Christoph Berger, University of Basel, Switzerland	
12:55-13:15	Discussion		
13:15-14:45	Lunch		Restaurant
14:45-16:15	PARALLEL SESSIONS (rotation of two 45 min-Sessions)		
	1. National decision-making for immunization programmes	Louise Henaff, Rudzani Muloiwa, Cape Town University	Charles Mérieux
	2. Clinical vaccinology: patients' problem solving	Alessandro Diana, Christiane Eberhardt, University Hospitals of Geneva (HUG)	Salon du Dr
	3. New approaches towards vaccination e-registries	Julia Stowe, UKHSA, UK, Carolina Danovaro, WHO Geneva, and Kari Johansen, Public Health Agency, Sweden	Simone Mérieux
	4. Monitoring immunization program performance	Jan Grevendonk, WHO Geneva	Nicole Mérieux
	5. Global and regional data for Global Strategies	Laure Dumolard, WHO Geneva	
	6. AEFI causality assessment	Madhav Balakrishnan, WHO, Geneva	O. Doumbo
16:15-16:45	Break		Restaurant
SESSION 11 – REACHING SPECIFIC GROUPS (part ½)			Chair: Kamel Senouci , University of Geneva
16:45-17:10	52. How to better reach the zero-dose or under-vaccinated children in LMICs	Kamel Senouci, University of Geneva	
17:10-17:30	Discussion		Charles Mérieux
17:30-17:45	Evaluation		conf. Room
18:30-20:00	Dinner upon registration		Restaurant
20:00	Bus to Hotels		

THURSDAY 21 MAY 2026

TBC

Bus from hotels to Les Pensières

SESSION 9 – UPDATES ON VACCINES (Part 4/4)

Chair: Edwin Asturias,
Children's Hospital
Colorado, USA

09:00-09:25	53. Cholera vaccines	Alejandro Cravioto, National Autonomous University of Mexico	Charles Mérieux
09:25-09:45	Discussion		
09:45-10:10	54. Meningococcal vaccines	Shamez Ladhani, UKHSA, UK	
10:10-10:30	Discussion		
10:30-11:00	Break		Restaurant
11:00-11:25	55. Tuberculosis vaccines	Helen McShane, University of Oxford, UK	Charles Mérieux
11:25-11:45	Discussion		

SESSION 11 – REACHING SPECIFIC GROUPS (part 2/2)

Chair: Kamel Senouci,
University of Geneva

11:45-12:10	56. Life-course vaccines: how to better reach individuals from childhood to elderly?	Pierre Vandamme, University of Antwerp, Belgium	Charles Mérieux
12:10-12:30	Discussion		
12:30-12:55	57. The determinants of vaccine acceptance	Eve Dubé, Université de Laval, Canada	Charles Mérieux
12:55-13:15	Discussion		
13:15 – 14:15	Lunch		Restaurant + O.DOumbo

SESSION 12 – COMMUNICATION AND VACCINE HESITANCY (part ½)

14:15-15:15	Small group exercise 7: Identifying & Collecting Evidence to advise on demand generation	Eve Dubé, Naveen Thacker, Kamel Senouci, Louise Henaff, Rudzani Muloiwa	Several rooms: please check on boards
15:15-16:15	Interactive Session 4 and Q&A	Justin Poncet and Darius Beucler, OPSCI, France	Charles Mérieux
16:15-16:30	Vaccination in the face of information chaos: from Analysis to Strategic Response		
16:15-16:30	Evaluation		
16:30-16:45	Break		Restaurant
16:45	Bus departure from les Pensières to hotels (check board for return bus from hotels to the Menthon Castle)		Meet at the Reception Lobby
18:15	Bus departure from Les Pensières to Château de Menthon Saint Bernard for visit of the castle and Gala Dinner		
22:30 and 00:00	Buses from Château de Menthon to les Pensières & Hotels		

FRIDAY 22 MAY 2026

TBC Bus from hotels to Les Pensières

SESSION 12: COMMUNICATION AND VACCINE HESITANCY (part 2/2)

Chair:
Louise Henaff,
UNIGE

09:00-09:20	58. Introduction to Communication Strategy design	Louise Henaff, University of Geneva	Dr. Charles Mérieux conf. Room
09:20-10:30	Small Group Exercise 8: Communication strategy design	Justin Poncet, Darius Beucler, Kamel Senouci, Louise Henaff, Eve Dubé, Naveen Thacker	Several rooms: check on boards
10:30-11:00	Break		Restaurant
11:00-11:25	59. Introduction to Empathetic Communication	Philipp Schmid, JITSUVAX, Netherlands	Charles Mérieux
11:25-12:30	Small Group Exercise 9: Empathetic Communication, Role play	Philipp Schmid, Eve Dubé, Alessandro Diana, Kamel Senouci, Louise Henaff, Rudzani Muloiwa	Several rooms: check on boards

SESSION 13: INNOVATION ON IMMUNIZATION

Chair:
Kamel Senouci,
UNIGE

12:30-12:55	60. Artificial Intelligence and vaccines	Edwin Asturias, Children's Hospital Colorado, USA	Dr. Charles Mérieux conf. Room
12:55-13:15	Discussion		
13:15-14:30	Lunch		Restaurant + O. Doumbo

SESSION 14: CLOSING

14:30-15:00	Evaluation		Charles Mérieux
15:00-15:45	Diploma ceremony, awarding of CME credits and closure of the course	Kamel Senouci, Director, ADVAC, University of Geneva	
TBC	Bus from Les Pensières to hotels (check boards for Schedule)		